Lebrikizumab Treatment in Adults with Asthma

Abstract

Many patients with asthma have uncontrolled disease despite treatment with inhaled glucocorticoids. One potential cause of the variability in response to treatment is heterogeneity in the role of interleukin-13 expression in the clinical asthma phenotype. We hypothesized that anti–interleukin-13 therapy would benefit patients with asthma who had a pretreatment profile consistent with interleukin-13 activity.